FB Nasdaq FB Facebook

Biotech Gainers: Novavax (NASDAQ:NVAX), OXiGENE Inc (NASDAQ:OXGN), Imprimis Pharmaceuticals (NASDAQ:IMMY), Oramed Pharmaceuticals (NASDAQ:ORMP)

Novavax (NASDAQ:NVAX) Director Richard Douglas acquired 50,000 shares of Novavax stock in a transaction that occurred on Tuesday, March 25th. Novavax, Inc. (NASDAQ:NVAX) stock performance was 8.47% in last session and finished the day at $4.48. Traded volume was 7,425,052 million shares in the last session and the average volume of the stock remained 5.05 million shares. The beta of the stock remained 2.15. Novavax, Inc. (NASDAQ:NVAX) insider ownership is 0.10%.

Trade-Ideas LLC identified OXiGENE Inc (NASDAQ:OXGN) as a “dead cat bounce” (down big yesterday but up big today) candidate. OXiGENE Inc (NASDAQ:OXGN) rose 8.07 percent to $3.75 yesterday on volume of 3.32 million shares. The intra-day range of the stock was $3.35 to $3.80. OXiGENE Inc (NASDAQ:OXGN) has a market capitalization of $57.14 million.

Imprimis Pharmaceuticals, Inc (NASDAQ:IMMY) a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s stock on Mar 25, 2014 reported a increase of 7.26% to the closing price of $7.53. Its fifty two weeks range is $3.01 -$10.00. The total market capitalization recorded $67.55 million. The overall volume in the last trading session was 46,196 million shares. In its share capital, Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has 8.96 million outstanding shares.

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced that IP Australia, the Australian government’s patent office, has issued the company its third patent in the country. The patent, titled “Methods and Compositions for Oral Administration of Exenatide,” covers oral exenatide compositions made using the company’s proprietary technology, including its ORMD-0901 oral exenatide capsule.Oramed has planned a comprehensive clinical program for ORMD-0901, with the goal of seeking approval in the U.S. and other territories. On Tuesday, shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) advanced 6.86% to close the day at $11.06. Company’s monthly performance is recorded as -26.51%. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) quarterly revenue growth is 3.85%.